United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 6 minute read Pharma Industry News Gilead Sciences to double down on CAR T with $7.8bn Arcellx acquisition Find out how Gilead Sciences’ $7.8 billion Arcellx acquisition reshapes the future of anito-cel and the competitive landscape in multiple myeloma. bySrinathFebruary 23, 2026